Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart mapping could make ablation more precise for lethal rhythm disorder

NCT ID NCT07573579

Disease control Sponsor: Liverpool Heart and Chest Hospital NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new technique called Dynamic Voltage Mapping (DVM) to better identify scar tissue in the heart that causes ventricular tachycardia (VT), a life-threatening heart rhythm. The approach uses catheters to create a personalized electrical map, aiming to guide ablation more accurately. Researchers will enroll 40 adults with VT who already have an implantable defibrillator, comparing DVM-guided ablation to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dynamic Voltage Mapping (a procedure using catheters to create a personalized electrical map of the heart)
What this could lead to
If successful, this mapping technique could help doctors more precisely destroy the heart tissue causing dangerous rhythms, potentially reducing the chance of VT returning after ablation.
What could go wrong
This is a small, early feasibility study with only 40 participants, so results may not apply to everyone. The technique may not prove better than standard care, and there are always risks with catheter procedures like bleeding or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Scheduled for clinically indicated VT ablation (due to sustained VT episodes or ICD therapies). * Willing and able to give informed consent for participation in the trial * Male or female aged between 18-85 * Ischaemic and non-ischaemic cardiomyopathy * ICD insitu Exclusion Criteria: * Unable or unwilling to consent * NYHA Class IV (end stage heart failure) * Metastatic cancer * End stage renal disease * Pregnant or breast feeding * Severe frailty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventricular tachycardia (VT) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ventricular tachycardia (VT)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Liverpool Heart and Chest Hospital NHS Foundation Trust

    Liverpool, L14 3PE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.